Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1926
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis ; day:19 ; month:5 ; year:2016 ; pages:1-10
Clinical pharmacokinetics ; (19.5.2016), 1-10
- Urheber
-
Overgaard, Rune V.
- Beteiligte Personen und Organisationen
-
Petri, Kristin C.
Jacobsen, Lisbeth V.
Jensen, Christine B.
SpringerLink (Online service)
- DOI
-
10.1007/s40262-016-0410-7
- URN
-
urn:nbn:de:1111-201605212431
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Overgaard, Rune V.
- Petri, Kristin C.
- Jacobsen, Lisbeth V.
- Jensen, Christine B.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery
Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland
The Influence of Normalization Weight in Population Pharmacokinetic Covariate Models
Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial
Liraglutide effect in reducing HbA1c and weight in Arab population with type2 diabetes, a prospective observational trial
Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus
Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400 mg
Reporting guidelines for population pharmacokinetic analyses
Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?
Liraglutide 3.0 mg (Saxenda©) for Weight Loss and Remission of Pre-Diabetes. Real-World Clinical Evaluation of Effectiveness among Patients Awaiting Bariatric Surgery
Voriconazole: A Review of Population Pharmacokinetic Analyses
Population pharmacokinetic modeling to understand antineoplastic treatment
Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery
Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland
The Influence of Normalization Weight in Population Pharmacokinetic Covariate Models
Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial
Liraglutide effect in reducing HbA1c and weight in Arab population with type2 diabetes, a prospective observational trial
Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus
Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400 mg
Reporting guidelines for population pharmacokinetic analyses
Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?
Liraglutide 3.0 mg (Saxenda©) for Weight Loss and Remission of Pre-Diabetes. Real-World Clinical Evaluation of Effectiveness among Patients Awaiting Bariatric Surgery
Voriconazole: A Review of Population Pharmacokinetic Analyses
Population pharmacokinetic modeling to understand antineoplastic treatment
Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery
Use of Liraglutide 3.0 mg for Weight Management in a Real-World Setting in Switzerland
The Influence of Normalization Weight in Population Pharmacokinetic Covariate Models
Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial
Liraglutide effect in reducing HbA1c and weight in Arab population with type2 diabetes, a prospective observational trial
Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus
Population pharmacokinetic modelling of imatinib in healthy subjects receiving a single dose of 400 mg
Reporting guidelines for population pharmacokinetic analyses
Liraglutide and polycystic ovary syndrome: is it only a matter of body weight?
Liraglutide 3.0 mg (Saxenda©) for Weight Loss and Remission of Pre-Diabetes. Real-World Clinical Evaluation of Effectiveness among Patients Awaiting Bariatric Surgery
Voriconazole: A Review of Population Pharmacokinetic Analyses